Latest News
MHRA approves Efmody for adrenal insufficiency treatment
...
European Commission approves Bristol Myers Squibb's Sotyktu for psoriatic arthritis
8 May 2026 - Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) announced on Friday that the European Commission has approved Sotyktu (deucravacitinib), alone or with methotrexate, for adults with active psoriatic arthritis (PsA) who had an in...
Rznomics receives FDA RMAT designation for HCC candidate RZ‑001
...
BioArctic and Eisai report FDA extension of Leqembi Iqlik review
8 May 2026 - Swedish research-based biopharma company BioArctic AB (STO:BIOA-B) and its Japanese partner Eisai Co Ltd (TYO:4523) announced on Friday that the US Food and Drug Administration (FDA) has extended by three months the review of the supplem...
Mezzion reveals pre-IND FDA feedback on udenafil development in ADPKD
8 May 2026 - South Korean biopharmaceutical company Mezzion Pharma Co Ltd on Thursday announced written feedback from the US Food and Drug Administration (FDA) following a pre-IND Type C Guidance meeting interaction for the development of udenafil in...